Analytical Data
-
基因名
TNFRSF10C
- Application
-
别名
TNFRSF10C；DCR1；LIT；TRAILR3；Tumor necrosis factor receptor superfamily member 10C
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O14798
-
表达区间
26-236aa
-
氨基酸序列
ATTAR QEEVPQQTVA PQQQRHSFKG EECPAGSHRS EHTGACNPCT EGVDYTNASN NEPSCFPCTV CKSDQKHKSS CTMTRDTVCQ CKEGTFRNEN SPEMCRKCSR CPSGEVQVSN CTSWDDIQCV EEFGANATVE TPAAEETMNT SPGTPAPAAE ETMNTSPGTP APAAEETMTT SPGTPAPAAE ETMTTSPGTP APAAEETMIT SPGTPA
-
分子量
27.4 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TNFRSF10C, also known as TRAIL receptor 2, is a member of the tumor necrosis factor receptor superfamily and has garnered significant interest in cancer research due to its role in regulating apoptosis and immune responses. This receptor selectively binds to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which has been recognized for its potential therapeutic applications in inducing cell death in cancer cells while sparing normal cells. The reconstitution of TNFRSF10C as a recombinant protein allows researchers to investigate its functional properties and interactions at the molecular level, providing insights into its signaling pathways and mechanisms of action. Furthermore, studying TNFRSF10C in recombinant form can facilitate the development of novel therapeutic agents aimed at enhancing tumor cell sensitivity to TRAIL-induced apoptosis. Recent studies have focused on the use of TNFRSF10C to overcome resistance mechanisms commonly observed in various cancer types. By elucidating the structure-function relationships of this receptor, scientists aim to design targeted therapies that exploit the apoptotic signaling pathways associated with TRAIL and its receptors, potentially leading to more effective cancer treatments. Overall, the research surrounding TNFRSF10C recombinant protein is vital for understanding cancer biology and developing innovative strategies for harnessing the body's immune system in the fight against cancer.
